Brilinta’s price cut 30%, Nexavar’s premium stays 1 year

MOHW to implement the ‘Amendment to the drug reimbursement list and reimbursement ceiling price table’

Entelon, with its reduced scope of reimbursement, voluntarily undergoes 2.6-2.9% price cut

Betmiga’s price, which had been fluctuating due to pricing lawsuits, will fall 23.6%

The insurance price of AstraZeneca Korea’s Brilinta tab.

 

90mg (ticagrelor) and Daxas tab.

 

500μg (roflumilast) will be reduced by 30% through the government’s ex-officio adjustment starting next month.

 

On the other hand, the price of Bayer Korea’s Nexavar 200mg (sorafenib tosylate) will be maintained at its level for one more year.

 

The price of Hanlim Pharm’s Entelon, whose indications for blood circulation and ophthalmologic diseases survived the Pharmaceutical Benefit Adequacy Assessment, was voluntarily lowered by 2.6-2.9% for each dose.

 

According to the industry, the Ministry of Health and Welfare is working to apply the ‘Amendment to the drug reimbursement list and reimbursement ceiling price table’ that contains the abovementioned changes by December 1st.

 

First, two drug items that were newly applied premiums will end in December.

 

The government applies a 59.5% premium or one year from the listing of the first generic.

 

For innovative pharmaceutical companies, the premium is set at 68% of the original drug price in the first year, then subsequently lowered to 53.55% after the term is terminated.

 

The two items subject to this form of price cuts are Handok Teva’s ‘Teva Bendamustine Inj.

 

(bendamustine hydrochloride)’ 25mg and 100mg.

 

The price of the two drugs will fall 10% each from coming March 1st, 2022.

 

One product will be maintained the premium pricing status.

 

The government allows premium pricing period extensions for drugs produced with identical ingredients by 3 or fewer companies.

 

The product that will be subject to an extension this time is Bayer Korea’s Nexavar 200mg.

 

Although Nexavar’s premium pricing period was set to expire, it was able to maintain its premium due to 3 or fewer companies producing drugs with identical ingredients.

 

Therefore, Nexavar’s premium pricing will be terminated on December 1st, 2023.

 

If the company applies for an evaluation to maintain its premium pricing, the government and HIRA would need to conduct an evaluation to determine whether to continue applying premium.

 

If the authorities decide to terminate the term, the price falls 23.5%.

 

The premium pricing period for Hanmi Pharmaceuticals’ Mirabeg 50mg (mirabegron) has also expired, and its price will be cut 21.3% from the first of next month.

 

Also, the price of Astellas Korea Betmiga (mirabegron), which had been fluctuating due to the suit filed by the company to cancel the government’s price cut decision, will be reduced by 23.6% on the same day due to the premium pricing period expiry.

 

Three items will undergo price cuts next month through ex-officio adjustments.

 

The government makes ex-officio price adjustments to the first-listed product and the product with the same route of administration, ingredient, and formulation as the first-listed product.

 

The three items are AstraZeneca Korea’s Brilinta tablets and Daxas tablet.

 

The price of Brilinta 90mg will be cut by 30%, 60mg by 29.9%, and Daxas 500μg by 30%.

 

The premium pricing period of the ex-officio price adjusted items is set to expire on November 2022.

 

When a generic is listed for the first time, the price of the first-listed product is given a 70% premium for a year, then returned to the original level.

 

If 3 or fewer companies sell the same product with the identical ingredient, the government allows the company to maintain the premium for up to 5 years until the number of companies becomes 4 or more.

 

The price of Brilinta will be reduced by 23.5% for each dose from November 21st, 2022, and the price of Daxas 500μg will be reduced by 23.5% from November 1st, 2022.